Article
FLT3 tyrosine kinase inhibitors.
International journal of hematology - 1 Aug 2005
Levis Mark, Small Donald
Abstract excerpt
The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome. Efforts to target this mutation and improve out-comes in this subgroup of AML patients have led to...
Topics
- Animals
- Enzyme Activation
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Prognosis
- Protein Kinase Inhibitors